Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.00USD
22 Jul 2016
Change (% chg)

-- (--)
Prev Close
$1.00
Open
--
Day's High
--
Day's Low
--
Volume
10,900
Avg. Vol
944,422
52-wk High
$5.59
52-wk Low
$0.64

Summary

Name Age Since Current Position

Kent Kresa

77 2016 Chairman of the Board

Matthew Pfeffer

57 2016 Chief Executive Officer, Chief Financial Officer, Director

Rose Alinaya

54 2016 Chief Accounting Officer

David Thomson

48 2002 Corporate Vice President, General Counsel, Corporate Secretary

Diane Palumbo

61 2004 Corporate Vice President - Human Resources

Michael Castagna

2016 Chief Commercial Officer

James Shannon

57 2015 Director

Ronald Consiglio

71 2003 Independent Director

Michael Friedman

72 2003 Independent Director

David MacCallum

77 2004 Independent Director

Henry Nordhoff

73 2005 Independent Director

Biographies

Name Description

Kent Kresa

Mr. Kent Kresa has been appointed Chairman of the Board at Mannkind Corporation effective February 18, 2016. Until this date, he served as Lead Independent Director at the Company from 2012. Prior to that, he served as Independent Director at the Company from June 2004. His work experience includes the following roles: Chairman Emeritus of Northrop Grumman Corporation, Chairman at Northrop Grumman Corporation (1990-October 2003), Chief Executive Officer at Northrop Grumman Corporation (January 1990- March 2003), President at Northrop Grumman Corporation (from 1987-September 2001), Director at General Motors Company (2003-August 2010), Director at Avery Dennison Corporation (December 2005-April 2010), Member of the Caltech Board of Trustees (from 1994), Board member at Fluor Corporation (from 2003) and Board member at several non-profit organizations and universities. He holds a Bachelor of Science degree and a Master of Science degree in Aeronautics and Astronautics, from Massachusetts Institute of Technology (MIT). He is a member of E.A.A. (Experimental Aircraft Association).

Matthew Pfeffer

Mr. Matthew Jonathan Pfeffer has been appointed Chief Executive Officer, Chief Financial Officer and Director at MannKind Corporation effective January 10, 2016. Until this date, he served as Chief Financial Officer, Vice President and IR Contact Officer at the Company from April 21, 2008. His work experience includes the following roles: Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. (March 200-April 2008), Chief Financial Officer of Cell Genesys, Inc. (from 1998), Employee at Price Waterhouse. He holds a Bachelors degree in Accounting from the University of California, Berkeley and is a Certified Public Accountant.

Rose Alinaya

Ms. Rose Alinaya has been appointed Chief Accounting Officer at Mannkind Corporation effective January 12, 2016. Until this date, she served as Vice President - Finance at the Company from March 2011 and prior to that as Controller at the Company from June 2003. She holds a Bachelor of Science degree in Accounting Information Systems from California State University, Northridge. She is a Certified Public Accountant.

David Thomson

Dr. David B. Thomson, Ph.D., J.D., is Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at a major Toronto law firm. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.

Diane Palumbo

Ms. Diane M. Palumbo is Corporate Vice President - Human Resources of MannKind Corporation. From July 2003 to November 2004, she was President of her own human resources consulting company. From June 1991 to July 2003, she held various positions with Amgen, Inc., a California-based biopharmaceutical company, including Senior Director, Human Resources. In addition, Ms. Palumbo has held Human Resources positions with Unisys and Mitsui Bank Ltd. of Tokyo. She holds a master’s degree in Business Administration from St. John’s University, New York and a bachelor’s degree, magna cum laude, also from St. John’s University.

Michael Castagna

Dr. Michael E. Castagna has been appointed Chief Commercial Officer at Mannkind Corporation effective March 14, 2016. He has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna was Executive Director of Bristol-Myers Squibb's Immunology franchise, where he served as co-lead to re-launch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna holds a Bachelors of Science degree in Pharmacy from Philadelphia College of Pharmacy (a part of University of the Sciences in Philadelphia), a Doctorate of Science degree in Pharmacy from Massachusetts College of Pharmacy (MCPHS University) and a MBA degree from Wharton School of Business at the University of Pennsylvania.

James Shannon

Dr. James S. Shannon, M.D., MRCP (UK), is an Director of the Company. He resigned as an Independent Director of MannKind Corporation effective May 1, 2012. He has more than 20 years experience at senior levels of the pharmaceutical industry and until his retirement in 2008 was Global Head of Drug Development for Novartis Pharma AG based in Basel, Switzerland. He entered the pharmaceutical industry in 1987 joining Sterling-Winthrop, Inc., where he held positions of increasing responsibility in the management of Research and Development ultimately serving as Senior Vice-President, Clinical Development. In 1994 he joined Sandoz, which later became Novartis, as Head of Drug Regulatory Affairs, where he held a number of positions including Head of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba and Sandoz and also Head of the Cardiovascular Strategic Team where he oversaw the design and implementation of the clinical trial program for Diovan. Subsequently he was appointed Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. Currently Dr. Shannon is also a director of Biotie Therapies Corp. and Endocyte, Inc. Dr. Shannon is trained in Medicine and Cardiology and received his undergraduate and postgraduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK).

Ronald Consiglio

Mr. Ronald J. Consiglio is an Independent Director of Mannkind Corporation., since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge. The Board believes that Mr. Consiglio’s knowledge and understanding of accounting and finance, his experience as a board member and executive officer at financial services firms, combined with his business acumen and judgment provide our Board with valuable accounting, financial and operational expertise and leadership skills.

Michael Friedman

Dr. Michael A. Friedman, M.D., is an Independent Director of MannKind Corporation., since December 2003. In 2014, Dr. Friedman completed a decade of service as the President and Chief Executive Officer of the City of Hope National Medical Center. Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company. From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998. He joined the board of Celgene Corporation in February 2011 and the board of Smith & Nephew plc in April 2013. Dr. Friedman received a bachelor of arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School. The Board believes Dr. Friedman’s business experience, including his experience as an executive officer at biopharmaceutical companies and a leading clinical and research center specializing in cancer and diabetes, and his service at the Food and Drug Administration, combined with his business acumen and judgment provide our Board with valuable scientific and operational expertise and leadership skills.

David MacCallum

Mr. David H. MacCallum is an Independent Director of MannKind Corporation., since June 2004. Since 2002, Mr. MacCallum has served as the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001, he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. From 2005 to October 2010, Mr. MacCallum served as a director of Zymogenetics, Inc. From 2002 to 2008, he served as a director of Vital Signs, Inc. Mr. MacCallum received an A.B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst. The Board believes that Mr. MacCallum’s knowledge and understanding of accounting and finance, his business experience in the investment banking industry, combined with his business acumen and judgment provide our Board with valuable accounting, financial and operational expertise and leadership skills.

Henry Nordhoff

Mr. Henry L. Nordhoff is an Independent Director of MannKind Corporation., since March 18, 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff’s business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership skills.